Description
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date
Date | Announcements |
---|---|
September 25, 2023 | Notice of Investor and Analyst Briefing 2023 FY Results |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Market Update |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Shareholder Briefing |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Becoming a substantial holder |
September 25, 2023 | CSL European Investor Site Tour Presentations |
September 25, 2023 | Ceasing to be a substantial holder |
September 25, 2023 | Update - Dividend/Distribution - CSL |
September 25, 2023 | Notification regarding unquoted securities - CSL |
September 25, 2023 | Application for quotation of securities - CSL |
September 25, 2023 | Final Director's Interest Notice |
September 25, 2023 | Notification of cessation of securities - CSL |
September 25, 2023 | Application for quotation of securities - CSL |
September 25, 2023 | Notification regarding unquoted securities - CSL |
September 25, 2023 | Change of Director's Interest Notice x 8 |
September 25, 2023 | Portfolio Update |
Load More
Load Less
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
EPS (Basic) | $ |
|
|
|
|
6.32 | 6.32 | 6.32 |
|
|
|
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Date | keys |
---|---|
08 March 2023 | Update on Indonesian subsidiary PT Bank Commonwealth Update on Indonesian subsidiary PT Bank Commonwealth |
09 March 2023 | ASB 2023 Half Year Financial Results Media Release |
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.